Medical Cannabis Tourism in Europe: Traveling for Treatment (2026)

A growing number of patients are traveling to European countries to access medical cannabis treatments not available in their home countries. Whether seeking specific formulations, strains, or simply legal access to cannabis-based medicines, medical cannabis tourism is an emerging but complex niche within European healthcare and travel. This guide covers the medical cannabis landscape across Europe, explains how patients can access treatment while traveling, discusses the Schengen Certificate system for cross-border medication transport, and highlights the countries with the most accessible medical cannabis programs for international patients.

Germany has the most developed medical cannabis market in Europe, with over 370,000 patients and a growing number of prescribers. Since legalization in 2017 for medical use and 2024 for recreational use, the German system has matured significantly. International patients visiting Germany cannot easily obtain a German prescription, but EU citizens with valid prescriptions from their home country may be able to fill them at German pharmacies. The range of products includes dried flower, oils, extracts, and capsules from multiple licensed producers.

The Netherlands has long been a pioneer in medical cannabis through its Office of Medicinal Cannabis (BMC), which supplies standardized cannabis products (Bedrocan) to pharmacies. Dutch medical cannabis is available by prescription and is among the most rigorously tested in the world. International patients can access Dutch medical cannabis with a valid prescription from their home country, though pharmacy acceptance varies. The BMC produces specific strains with standardized THC and CBD content, ensuring consistent dosing.

Italy, Poland, Denmark, and the Czech Republic all have operational medical cannabis programs, though accessibility varies significantly. Italy allows doctors to prescribe cannabis for a range of conditions and has both domestic production and imports. Poland has had a medical cannabis program since 2017, primarily relying on imports. Denmark ran a medical cannabis pilot program that has been extended. The Czech Republic has a well-established medical program with domestic cultivation. In each case, access for international patients requires advance planning and coordination with local healthcare providers.

The Schengen Certificate system is the key legal framework for patients traveling within Europe with prescribed cannabis. Under Article 75 of the Schengen Convention, patients can carry up to 30 days' supply of prescribed controlled substances across Schengen borders. The certificate must be issued by the health authority of the prescribing country, specify the medication and dosage, and be presented at border crossings if requested. Not all countries process cannabis-specific certificates efficiently, so patients should apply well in advance.

Practical considerations for medical cannabis patients traveling in Europe: carry your prescription and any certificates at all times; keep medication in original pharmacy packaging with clear labeling; research the specific legal status of your medication in each country on your itinerary; contact the embassy or consulate of your destination countries for guidance; and consider consulting with a specialized medical cannabis travel advisor. The European landscape is evolving rapidly, with new programs and policy changes occurring regularly.